. 2021 Mar 1;13(5):1029. doi: 10.3390/cancers13051029

Table 2.

Univariate analysis for selected gene mutations and copy number alterations against clinicopathologic variables. “Group 1” indicates the referent variable, whilst “Group 2” indicates the comparison variable. Only comparisons where p < 0.05 are shown. NSND = non-smoker and non-drinker; SD = smokers and/or drinker; LN = lymph node; LVI = lymphovascular invasion; PNI = perineural invasion; ECS = extracapsular spread; OR = odds ratio, CI = confidence interval; * p < 0.05.

Group 1 vs. Group 2	Gene	Group 1 n (%)	Group 2 n (%)	OR (95% CI)	p
Male vs. Female	TP53 mut	67/100 (67.0)	39/76 (51.3)	1.9 (1.0–3.7)	0.043 *
Male vs. Female	CASP8 mut	3/100 (3.0)	11/76 (14.5)	0.2 (0.0–0.7)	0.009 *
Smokers vs. Non-smokers	CDKN2A mut	15/90 (16.7)	27/86 (31.4)	0.4 (0.2–0.9)	0.033 *
Drinkers vs. Non-drinkers	CASP8 mut	4/97 (4.1)	10/79 (12.7)	0.3 (0.1–1.1)	0.050 *
Drinkers vs. Non-drinkers	LAMA4 mut	1/97 (1.0)	8/79 (10.1)	0.1 (0.0–0.7)	0.012 *
NSND vs. SD	CDKN2A mut	21/59 (35.6)	21/117 (17.9)	2.5 (1.2–5.5)	0.014 *
	EGFR amp	10/59 (16.9)	6/117 (5.1)	3.7 (1.2–13.3)	0.023 *
	BRCA2 del	7/59 (11.9)	2/117 (1.7)	7.6 (1.4–77.8)	0.007 *
T3/4 tumours vs. T1/2 tumours	CDKN2A mut	26/71 (36.6)	16/105 (15.2)	3.2 (1.5–7.1)	0.002 *
	CDKN2A del	7/71 (9.9)	0/105 (0)	Inf (2.3–Inf)	0.001 *
	BRCA2 del	8/71 (11.3)	1/105 (1.0)	13 (1.7–590.0)	0.003 *
LN+ vs. LN−	TP53 mut	48/61 (78.7)	58/115 (50.4)	3.6 (1.7–8.1)	<0.001 *
LN+ vs. LN−	BRCA2 del	7/61 (11.5)	2/115 (1.7)	7.2 (1.3–73.5)	0.009 *
LVI+ vs. LVI−	TP53 mut	15/18 (83.3)	91/158 (57.6)	3.7 (1.0–20.0)	0.042 *
LVI+ vs. LVI−	NCOR2 mut	4/18 (22.2)	8/156 (5.1)	5.3 (1.0–22.9)	0.023 *
PNI+ vs. PNI−	EGFR amp	7/32 (21.9)	9/144 (6.2)	4.2 (1.2–13.9)	0.012 *
ECS+ vs. ECS−	CDKN2A mut	9/20 (45.0)	33/156 (21.2)	3 (1.0–8.8)	0.026 *
	TP53 mut	19/20 (95.0)	87/156 (55.8)	15 (2.3–633.0)	<0.001 *
	EGFR amp	5/20 (25.0)	11/156 (7.1)	4.3 (1.0–16.0)	0.022 *
	BRCA2 del	4/20 (20.0)	5/156 (3.2)	7.4 (1.3–38.4)	0.011 *